SE0301087D0 - New monoclonal antibody - Google Patents

New monoclonal antibody

Info

Publication number
SE0301087D0
SE0301087D0 SE0301087A SE0301087A SE0301087D0 SE 0301087 D0 SE0301087 D0 SE 0301087D0 SE 0301087 A SE0301087 A SE 0301087A SE 0301087 A SE0301087 A SE 0301087A SE 0301087 D0 SE0301087 D0 SE 0301087D0
Authority
SE
Sweden
Prior art keywords
integrin
fragment
monoclonal antibody
extracellular
domain
Prior art date
Application number
SE0301087A
Other languages
English (en)
Inventor
Evy Lundgren-Aakerlund
Original Assignee
Cartela Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cartela Ab filed Critical Cartela Ab
Priority to SE0301087A priority Critical patent/SE0301087D0/sv
Publication of SE0301087D0 publication Critical patent/SE0301087D0/sv
Priority to JP2006508020A priority patent/JP5064025B2/ja
Priority to CA2522645A priority patent/CA2522645C/en
Priority to US10/553,226 priority patent/US7452677B2/en
Priority to PCT/SE2004/000580 priority patent/WO2004089990A1/en
Priority to AT04727464T priority patent/ATE542889T1/de
Priority to AU2004228605A priority patent/AU2004228605B2/en
Priority to EP04727464A priority patent/EP1613659B1/en
Priority to US12/285,587 priority patent/US8012696B2/en
Priority to US13/193,293 priority patent/US8563255B2/en
Priority to US14/032,900 priority patent/US9365649B2/en
Priority to US15/156,032 priority patent/US10087253B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G01N2333/7055—Integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
SE0301087A 2003-04-14 2003-04-14 New monoclonal antibody SE0301087D0 (sv)

Priority Applications (12)

Application Number Priority Date Filing Date Title
SE0301087A SE0301087D0 (sv) 2003-04-14 2003-04-14 New monoclonal antibody
EP04727464A EP1613659B1 (en) 2003-04-14 2004-04-14 New monoclonal antibody capable of binding integrin alpha 10 beta 1
PCT/SE2004/000580 WO2004089990A1 (en) 2003-04-14 2004-04-14 New monoclonal antibody capable of binding integrin alpha 10 beta 1
CA2522645A CA2522645C (en) 2003-04-14 2004-04-14 New monoclonal antibody capable of binding integrin alpha10beta1
US10/553,226 US7452677B2 (en) 2003-04-14 2004-04-14 Monoclonal antibody capable of binding integrin alpha 10 beta 1
JP2006508020A JP5064025B2 (ja) 2003-04-14 2004-04-14 インテグリンα１０β１を結合することができる新規モノクローナル抗体
AT04727464T ATE542889T1 (de) 2003-04-14 2004-04-14 Neuer monoklonaler antikörper, der dazu in der lage ist, integrin-alpha-10-beta-1 zu binden
AU2004228605A AU2004228605B2 (en) 2003-04-14 2004-04-14 New monoclonal antibody capable of binding integrin alpha 10 beta 1
US12/285,587 US8012696B2 (en) 2003-04-14 2008-10-09 Monoclonal antibody capable of binding integrin alpha 10 beta 1
US13/193,293 US8563255B2 (en) 2003-04-14 2011-07-28 Monoclonal antibody capable of binding integrin alpha 10 beta 1
US14/032,900 US9365649B2 (en) 2003-04-14 2013-09-20 Monoclonal antibody capable of binding integrin alpha 10 beta 1
US15/156,032 US10087253B2 (en) 2003-04-14 2016-05-16 Monoclonal antibody capable of binding integrin alpha 10 beta 1

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0301087A SE0301087D0 (sv) 2003-04-14 2003-04-14 New monoclonal antibody

Publications (1)

Publication Number Publication Date
SE0301087D0 true SE0301087D0 (sv) 2003-04-14

Family

ID=20291013

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0301087A SE0301087D0 (sv) 2003-04-14 2003-04-14 New monoclonal antibody

Country Status (3)

Country Link
US (5) US7452677B2 (sv)
AT (1) ATE542889T1 (sv)
SE (1) SE0301087D0 (sv)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4912528B2 (ja) * 1998-04-02 2012-04-11 キシンテラ、アクチボラグ インテグリンヘテロ二量体およびそのサブユニット
CA2488423A1 (en) * 2002-06-17 2003-12-24 Cartela Ab Methods and uses of the integrin alpha 10 chain, for preventing progression of atherosclerosis plaque formation
SE0301087D0 (sv) * 2003-04-14 2003-04-14 Cartela Ab New monoclonal antibody
JPWO2005073385A1 (ja) * 2004-01-29 2008-01-10 独立行政法人産業技術総合研究所 遺伝子導入効率を上昇させるための組成物および方法
US20090155229A1 (en) * 2004-12-06 2009-06-18 Avner Yayon Chondrocyte-based implant for the delivery of therapeutic agents
US8568761B2 (en) * 2005-07-15 2013-10-29 Cormatrix Cardiovascular, Inc. Compositions for regenerating defective or absent myocardium
JP2009508596A (ja) 2005-09-19 2009-03-05 ヒストジェニックス コーポレイション 細胞支持基材及びその調製方法
US20100055114A1 (en) * 2006-12-15 2010-03-04 Evy Lundgren-Akerlund Use of integrin alpha 10 binding antibody to modulate extracellular matrix (cartilage) turnover
US20090054984A1 (en) 2007-08-20 2009-02-26 Histogenics Corporation Method For Use Of A Double-Structured Tissue Implant For Treatment Of Tissue Defects
US8685107B2 (en) 2007-07-03 2014-04-01 Histogenics Corporation Double-structured tissue implant and a method for preparation and use thereof
US8802121B2 (en) * 2009-06-02 2014-08-12 Surmodics, Inc. Silane-functionalized hydrophobic α(1→4)glucopyranose polymers and polymeric matrices for implantation or injection
PT2467401T (pt) 2009-08-19 2017-04-26 Merck Patent Gmbh Anticorpos para a deteção de complexos de integrina em material ffpe
US8883210B1 (en) 2010-05-14 2014-11-11 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US10130736B1 (en) 2010-05-14 2018-11-20 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US9352003B1 (en) 2010-05-14 2016-05-31 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US8834928B1 (en) 2011-05-16 2014-09-16 Musculoskeletal Transplant Foundation Tissue-derived tissugenic implants, and methods of fabricating and using same
JP6329911B2 (ja) * 2012-02-22 2018-05-23 ブレインステム バイオテック リミテッド 星状膠細胞作製のためのミクロｒｎａ
US20170121687A1 (en) * 2014-04-23 2017-05-04 Agency For Science, Technology And Research Methods of cellular reprogramming
US10077420B2 (en) 2014-12-02 2018-09-18 Histogenics Corporation Cell and tissue culture container
DK3258964T3 (da) * 2015-02-16 2021-02-08 Xintela Ab Detektion og behandling af maligne tumorer i CNS
WO2016187413A1 (en) 2015-05-21 2016-11-24 Musculoskeletal Transplant Foundation Modified demineralized cortical bone fibers
JP7098602B2 (ja) * 2016-08-17 2022-07-11 キシンテラ、アクチボラグ 神経幹細胞のマーカー
DK3573630T3 (da) * 2017-01-27 2021-06-07 Xintela Ab Forebyggelse og behandling af skader eller sygdom i knogler og brusk
NZ760232A (en) 2017-06-07 2023-05-26 Regeneron Pharma Compositions and methods for internalizing enzymes
BR112020016005A2 (pt) 2018-02-07 2020-12-15 Regeneron Pharmaceuticals, Inc. Método de administração de uma proteína terapêutica ao sistema nervoso central, proteína terapêutica multidomínio, polinucleotídeo, vetor de terapia gênica, e, uso de um nucleotídeo que codifica a proteína terapêutica multidomínio

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3725616A1 (de) 1987-08-03 1989-02-16 Philips & Du Pont Optical Aufbewahrungskassette fuer einen plattenfoermigen informationstraeger
EP0330506A3 (en) 1988-02-26 1990-06-20 Dana Farber Cancer Institute Vla proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5686069A (en) 1990-10-15 1997-11-11 Mycogen Corporation Protein toxins active against lepidopteran pests
US5310874A (en) 1991-05-03 1994-05-10 The Scripps Research Institute Integrin α subunit cytoplasmic domain polypeptides and antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
CA2117780A1 (en) 1992-04-10 1993-10-28 Paul F. Goetinck Cartillage matrix protein and methods for use
DE59308118D1 (de) 1992-12-01 1998-03-12 Merck Patent Gmbh Koordinations-katalysatorsysteme
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
AU6639394A (en) 1993-04-26 1994-11-21 Children's Medical Center Corporation A method for rapid formation and isolation of focal adhesion complexes
US5910486A (en) * 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US5731425A (en) * 1994-10-28 1998-03-24 Eastman Kodak Company Polypeptide surface marker for cells
US5698762A (en) 1994-12-09 1997-12-16 Dauerman; Leonard Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons
US5853987A (en) 1995-04-24 1998-12-29 The Texas A & M University System Decorin binding protein compositions and methods of use
WO1997031653A1 (en) 1996-03-01 1997-09-04 Beth Israel Deaconess Medical Center Diagnosis and treatment of metastic breast carcinoma
US5843436A (en) 1996-04-22 1998-12-01 The Trustees Of Columbia University, In The City Of New York Method of preventing and treating bacterial infection of sutures and prosthetic devices, and promoting ingress of leukocytes into tumor foci
AU727606B2 (en) * 1996-07-12 2000-12-14 Genentech Inc. Gamma-heregulin
US5928945A (en) * 1996-11-20 1999-07-27 Advanced Tissue Sciences, Inc. Application of shear flow stress to chondrocytes or chondrocyte stem cells to produce cartilage
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
US20060122373A1 (en) 1997-04-04 2006-06-08 Millennium Pharmaceuticals, Inc. Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof
US6287857B1 (en) * 1998-02-09 2001-09-11 Genzyme Corporation Nucleic acid delivery vehicles
JP4912528B2 (ja) 1998-04-02 2012-04-11 キシンテラ、アクチボラグ インテグリンヘテロ二量体およびそのサブユニット
US20030055231A1 (en) 1998-10-28 2003-03-20 Jian Ni 12 human secreted proteins
US20030129685A1 (en) 1998-10-28 2003-07-10 Jian Ni 12 human secreted proteins
PT1156827E (pt) 1999-03-01 2007-01-31 Halogenetics Inc Utilização de composições compreendendo cidc como radiossensibilizadores no tratamento de doenças neoplásicas
AU5014700A (en) 1999-05-28 2000-12-18 Millennium Pharmaceuticals, Inc. Novel integrin alphasubunit and uses thereof
JP2001354699A (ja) 2000-06-12 2001-12-25 Teijin Ltd アンギオテンシンｉｉと結合する抗体
AU2001266915A1 (en) 2000-06-14 2001-12-24 Case Western Reserve University Probes for chondrogenesis
US7153944B2 (en) 2000-07-31 2006-12-26 The General Hospital Corporation High affinity integrin polypeptides and uses thereof
AU2003222556A1 (en) 2002-04-12 2003-12-19 Cartela R & D Ab Knockout mice and their use
US6847844B2 (en) 2002-06-06 2005-01-25 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of data communication with implanted device and associated apparatus
CA2489212C (en) 2002-06-14 2012-08-14 Cartela Ab Marker for stem cells and its use
EP2365004B1 (en) 2002-06-21 2016-01-06 Johns Hopkins University School of Medicine Membrane associated tumor endothelium markers
SE0301087D0 (sv) * 2003-04-14 2003-04-14 Cartela Ab New monoclonal antibody

Also Published As

Publication number Publication date
US20160319023A1 (en) 2016-11-03
ATE542889T1 (de) 2012-02-15
US7452677B2 (en) 2008-11-18
US10087253B2 (en) 2018-10-02
US9365649B2 (en) 2016-06-14
US20120034625A1 (en) 2012-02-09
US20090185978A1 (en) 2009-07-23
US20060127398A1 (en) 2006-06-15
US8012696B2 (en) 2011-09-06
US8563255B2 (en) 2013-10-22
US20140099716A1 (en) 2014-04-10

Similar Documents

Publication Publication Date Title
SE0301087D0 (sv) New monoclonal antibody
TW200714711A (en) Anti-cd-20 monoclonal antibody
EP1064303A4 (en) MONOCLONAL ANTIBODIES SPECIFIC TO THE EXTRACELLULAR DOMAIN OF THE PROSTATE SPECIFIC MEMBRANEANT
IL215027A0 (en) ANTI-zB7R1 ANTIBODY
CO5700152A1 (es) Nuevos anticuerpos anti-igf-ir y sus usos
UA97946C2 (ru) Моноклональное антитело, специфически связывающееся с внеклеточным доменом ilt7 человека
RS52769B (sr) Kompozicije i postupci za povećanje mineralizacije kostiju
BRPI0413119A (pt) uso de anticorpos com adcc otimizada para tratar pacientes debilitados
TW200741000A (en) Method of producing lymphocytes
IL193212A0 (en) Anti-idiotypic antibody which neutralizes the inhibitory activity of an inhibitory antibody directed against the c1 domain of factor viii
Reyes-Botella et al. Antigenic phenotype of cultured human osteoblast-like cells
ATE283349T1 (de) Isolierung von vorläuferzellen und deren verwendung zum wiederaufbau von bindegewebe
SG157312A1 (en) High affinity binding site of hgfr and methods for identification of antagonists thereof
DE602004016522D1 (de) Behandlung und diagnose von neoplasien mit tslp (thymic stromal lymphopoietin)
MXPA05009743A (es) Composiciones con actividad hematopoyetica e inmune.
RU2010152690A (ru) Белки, связывающие рецептор интерлейкина-21
DK1064018T3 (da) Anvendelsen af isolerede domæner af Type IV kollagen til at modificere celle- og vævsinteraktioner
DE60331882D1 (de) Antikörper zur Identifizierung und/oder Isolierung von wenigstens einer Zellpopulation ausgewählt aus hämatopoetischen Stammzellen, neuronalen Stammzellen, progenitoren neuronalen Zellen, Mesenchym-Stammzellen und mesenchym-progenitoren Stammzellen
DE60017263D1 (de) Verfahren zur reinigung von wasser, dafür geeignete bakterien und deren verwendung
ATE410448T1 (de) Neues peptid und pharmazeutische zusammensetzung, die dieses peptid enthält
ATE396405T1 (de) Verfahren und verwendung eines antikörpers zum nachweis von allergien
CA2522645A1 (en) New monoclonal antibody capable of binding integrin alpha10beta1
ATE476447T1 (de) Verfahren und zusammensetzungen zur modulation und zum nachweis von wisp-aktivität
DE602007013289D1 (de) Peptide und polypeptide mit verbesserter stabilität, die sich für die regeneration des nervensystems eignen
SE9904236D0 (sv) Immunoassay